Background: Neuropsychiatric systemic lupus erythematosus (NPSLE) and neuromyelitis optica spectrum disorder (NMOSD) share overlapping clinical features including optic neuritis, transverse myelitis, and area postrema syndrome. A subset of NPSLE patients harbor aquaporin-4 (AQP4) antibodies, but clinical significance of AQP4-IgG subclass distribution (IgG1 vs IgG3 predominance) in CSF remains unexplored as a predictive biomarker for CNS demyelinating overlap.
Hypothesis: Serial CSF sampling in NPSLE patients with borderline or low-titer serum AQP4 antibodies will reveal that a shift from IgG1-dominant to IgG3-dominant AQP4-IgG subclass distribution precedes NMOSD-pattern MRI lesion appearance by 8–20 weeks. This IgG subclass transition reflects complement-fixing capacity escalation (IgG3 >> IgG1 for C1q binding) and marks the transition from subclinical astrocytopathy to clinically significant demyelination.
Testable Predictions:
- NPSLE patients who develop NMOSD-overlap lesions will show CSF AQP4-IgG3/IgG1 ratio >2.0 at least 8 weeks before first MRI-visible lesion, versus ratio <0.5 in non-converters (AUC >0.85).
- CSF complement split product C5a levels will correlate with AQP4-IgG3 fraction (r >0.70, p <0.001), confirming the complement-mediated pathogenic mechanism.
- Patients with IgG3-dominant AQP4 CSF profiles will show preferential longitudinally extensive transverse myelitis (LETM) pattern, while IgG1-dominant profiles associate with cerebral microangiopathic patterns typical of isolated NPSLE.
- Early eculizumab or ravulizumab intervention at t





























